Abstract:Objective To explore the feasibility of dual-modality probe to in vivo target angiogenesis of gastric cancer on MRI and near-infrared fluorescence (NIRF) optical imaging.Methods Cy5.5-GX1 with magnetic Fe3O4 nanoparticles were conjugated,resulting in dual-modality probe DPs.The hydrodynamic size and Zeta potential of DPs were analyzed by nano-ZS.Twelve male nude mice were obtained and established gastric adenocarcinoma subcutaneous transplantation tumor model.Twelve nude mice were divided into experimental group and control group (n=6 for each) by using completely random experimental design,then intravenously injected the same volume of DPs and Fe3O4-Cy5.5.MRI was applied before and 4,8,12,18,24 hours respectively after injections of nanoparticles to follow the changes of signals.For the evaluation of the MR images,the contrast to noise ratio (CNR) were calculated,and the different groups were compared with analysis of variance.MR images of the same level were selected before and 12 h after injections of nanoparticles in two groups and the percentage of reduced pixels was calculated,which were compared with the paired t test.At the same time,the time-resolved accumulation of the nanoparticles in the tumors were observed by using in vivo fluorescence imaging at 0,4,8,12,18,24 hours after injecting nanoparticles,respectively.Then tumor and normal tissues were collected,and ex vivo optical imaging and histopathology were performed on the tissues.Results At room temperature,the hydrodynamic size of Fe3Ox-Cy5.5 was (38.23±0.06) nm and the Zeta potential was (0.29±0.16) mV,and the hydrodynamic size of DPs was (39.49±0.16) nm and the Zeta potential was (-4.15±0.79) mV.The coupled rate of DPs with polypeptide was＞90％.The MRI signals of reticuloendothelial system were reduced significantly in experiment and control group.The tumor CNR of experiment group before and 4,8,12,18,24 h after injection were 18.27±2.19,18.40±2.00,10.22±1.97,9.25±0.44,20.28± 1.46 and 22.41 ± 1.71 (F=49.55,P＜0.01),and the CNR at 8 h and 12 h after the injection of probe were significantly lower than that before injection.The tumor CNR of control group at the same time were 13.52± 1.05,11.38± 1.28,13.03± 1.38,12.89± 1.20,12.06±0.81 and 13.58± 1.74 (F=2.306,P＞0.05).The percentage of MR signals decrease of the tumor periphery and central area were (33.0±2.7)％ and (22.0±1.6)％,respectively in experiment group and that of control group were(8.3± 1.2)％ and (3.8±0.9)％ respectively (t values were-7.872 and 6.678,P＜0.01).The tumor fluorescence intensity of experimental group showed the high contrast to background tissue during 2 to 48 h p.i,but there was no significant difference in control group.Furthermore,ex vivo evaluation of excised organs showed DPs was predominantly taken up by the tumor and lung at 48 h p.i.Tumor neovascularization was mainly distributed in the tumor periphery area.Iron-positive cells were detected in the tumor of experiment group.The normal kidney tissues of the two groups and the tumor of control group were consistently negative for iron staining.Conclusion DPs can selectively be delivered into gastric cancer and this novel receptor-targeted nanoparticle could be used for MRI and NIRF optical imaging.

Lung Neoplasm Targeted Nanotechnology MR Contrast Medium: Experimental Study of Mice Model

Study on angiogenesis-targeting paramagnetic nanoliposomes in MRI for diagnosis of pulmonary carcinoma

Ultra-Small and Metabolizable Near-Infrared Au/Gd Nanoclusters for Targeted FL/MRI Imaging and Cancer Theranostics

MR Study of Transplanted Lung Cancer with Small Animal Coil

A Targeted Nanoglobular Contrast Agent from Host-Guest Self-Assembly for MR Cancer Molecular Imaging.

Nanoparticle-based MRI of metastatic human hepatocellular carcinoma: Targeting survivin gene with siRNA in an animal model

Comparison of Tumor Neovasculature-Targeted Paramagnetic Nanoliposomes for MRI in Mice Xenograft Models.

Development of a New Specific MR Contrast Agent Gd-DTPA-BSA-chTNT and Its Application in Vivo Molecular MR Imaging in the Nude Mouse Model Implanted with Human Breast Cancer

In Vivo MR Imaging of Tumor by Using Fe3O4 Nanoparticles Bearing with Different Surface Ligand As Contrast Agent

Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.

Dual Integrin Αvβ 3 and NRP-1-Targeting Paramagnetic Liposome for Tumor Early Detection in Magnetic Resonance Imaging

RGD-targeted Paramagnetic Liposomes for Early Detection of Tumor: in Vitro and in Vivo Studies.

Non-invasive visualization of tumors in the mouse liver using a novel nanoparticle contrast enhanced micro-CT imaging procedure

Folate-poly-L-lysine- Gd-DTPA As MR Contrast Agent for Tumor Imaging Via Folate Receptor-Targeted Delivery

2-Deoxy-d-glucose Modified Supermagnetic Iron Oxide Nanoparticles Enhance the Contrasting Effect on MRI of Human Lung Adenocarcinoma A549 Tumor in Nude Mice

Ultrasound and magnetic resonance imaging of cyclic arginine glycine aspartic acid-gadopentetic acid-polylactic acid in human breast cancer by targeting αvβ3 in xenograft-bearing nude mice

In Vivo Dual-Modality MR and Near-Infrared Fluorescence Imaging of Gastric Cancer Neovasculature with Targeted Multi-Functionalized Nanoparticles

Visualization of nonsmall-cell lung cancer by near-infrared fluorescence imaging with tumor-targeting peptide ABT-510

In Vivo MR Imaging and Pathology Study in Mice Model Labeled with SPIO

Radiosensitization and Micro CT Imaging of Multifunctional Gold Nanoparticles in Lung Adenocarcinoma A549 Cell: an in Vivo Animal Study.